Methods: Here, we report on a small cohort of seven AML patients refractory to multiple lines (range 3-7) of therapy, who received CXCR4-directed ERT with [177Lu]Pentixather in combination with TBI and chemotherapy prior to alloSCT. The gene discussed is CXCR4; the disease is acute myeloid leukemia.